Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy

Author:

Quach Hang1ORCID,Nooka Ajay2,Samoylova Olga3,Venner Christopher P.4,Kim Kihyun5,Facon Thierry6,Spencer Andrew7,Usmani Saad Z.8,Grosicki Sebastian9,Suzuki Kenshi10,Delimpasi Sosana11,Weisel Katja12,Obreja Mihaela13,Zahlten‐Kumeli Anita13,Mateos Maria‐Victoria14ORCID

Affiliation:

1. St. Vincent’s Hospital University of Melbourne Melbourne Victoria Australia

2. Winship Cancer Institute Emory University Atlanta GA USA

3. Nizhniy Novgorod Region Clinical Hospital Nizniy Novgorod Russia

4. Cross Cancer Institute University of Alberta Edmonton Alberta Canada

5. Samsung Medical Center Sungkyunkwan University Seoul Korea

6. Hôpital Claude Huriez Lille France

7. Alfred Health‐Monash University Melbourne Australia

8. Atrium Health Charlotte NC USA

9. Silesian Medical University Katowice Poland

10. Japanese Red Cross Medical Center Tokyo Japan

11. General Hospital Evangelismos Athens Greece

12. University Medical Center Hamburg‐Eppendorf Hamburg Germany

13. Amgen, Inc. Thousand Oaks CA USA

14. University Hospital Salamanca/IBSAL Salamanca Spain

Funder

Amgen

Publisher

Wiley

Subject

Hematology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3